Mr Matthew L Larrabee > Dechert LLP > New York, United States > Lawyer Profile
Dechert LLP Offices
Three Bryant Park, 1095 Avenue of the Americas
NEW YORK, NY 10036-6797
NEW YORK
United States
- Firm Profile
- Go to...
Mr Matthew L Larrabee
Work Department
Litigation
Position
Partner
Career
Matthew L. Larrabee has more than 30 years of experience in trial and appellate practice and currently serves as the firm’s Deputy Chair for Strategic Growth. He previously served as Chair of the global litigation practice group. He has served as lead trial counsel for many leading businesses in the financial services, mutual fund, hedge fund, private equity and technology industries.
Mr. Larrabee has significant experience in financial services litigation, securities class actions, internal investigations, shareholder derivative litigation, mergers and acquisitions, appraisal actions, and other complex commercial litigation. He has tried a wide range of cases, and argued significant appeals, in state and federal courts across the country. Mr. Larrabee speaks more than a dozen times a year to clients and at industry conferences on litigation risks, particularly those facing the financial services industry. He is also co-author of Mutual Fund Litigation and Insurance Guide (LexisNexis, 2016), a book that examines the legal risks faced by the mutual fund industry.
Memberships
- American Bar Association
- American Law Institute
Education
- University of California, Davis, B.A., 1977, with Honors
- University of California Hastings College of the Law, J.D., 1980, Thurston Honor Society, Order of the Coif, Editor-in-Chief of the Hastings Law Journal
Lawyer Rankings
United States > Dispute resolution > Securities litigation: defense
The trial, investigations and securities practice at Dechert LLP has a deep bench of partners who represent a diverse range of clients, among them leading mutual funds and corporate issuers of securities. Practice head David Kistenbroker
and key partner Joni Jacobsen, who work out of both the Chicago and New York offices, are highly praised by peers. They are currently handling a class action against Antares Pharma, Inc. that alleges the company provided insufficient information to the FDA in support of testosterone replacement therapy Xyosted and subsequently overstated the drug’s approval prospects, rendering public statements false and misleading. Regulatory enforcement specialist Michael Doluisio in Philadelphia and New York litigation partner Andrew Levander are acting for AmerisourceBergen Corp. in a shareholder derivative suit filed in Delaware Chancery Court accusing the company breaching its fiduciary duties by failing to oversee compliance with federal regulations concerning distribution of controlled substances and their contributing to the opioid epidemic. Matthew Larrabee, Andrew Levander and Linda Goldstein are the key practitioners in New York. In San Francisco, corporate governance litigation partner Richard Horvath and securities and antitrust partner Josh Hess are the main contacts.
Lawyer Rankings
Top Tier Firm Rankings
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Intellectual property > Trademarks: non-contentious (including prosecution, portfolio management and licensing)
- Investment fund formation and management > Mutual/registered/exchange-traded funds
- Dispute resolution > Product liability, mass tort and class action - defense: pharmaceuticals and medical devices
- Real estate > Real estate finance
Firm Rankings
- Media, technology and telecoms > Cyber law (including data privacy and data protection)
- Dispute resolution > Product liability, mass tort and class action - defense: toxic tort
- Dispute resolution > Securities litigation: defense
- Finance > Structured finance: securitization
- Antitrust > Civil litigation/class actions: defense
- Dispute resolution > E-discovery
- Finance > Fintech
- Dispute resolution > General commercial disputes
- Dispute resolution > International litigation
- Tax > International tax
- Healthcare > Life sciences
- Dispute resolution > M&A litigation: defense
- Antitrust > Merger control
- M&A/corporate and commercial > Private equity buyouts: large deals ($500m+)
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Finance > Restructuring (including bankruptcy): corporate
- Tax > US taxes: non-contentious
- Finance > Capital markets: debt offerings
- Finance > Capital markets: equity offerings
- Finance > Capital markets: global offerings
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Environment > Environment: transactional
- Dispute resolution > International arbitration
- M&A/corporate and commercial > M&A: large deals ($1bn+)
- Intellectual property > Patents: prosecution (including re-examination and post-grant proceedings)
- International Trade > Customs, export controls and economic sanctions
- Dispute resolution > Leading trial lawyers
- Intellectual property > Patents: litigation (full coverage)
- Investment fund formation and management > Private equity funds (including venture capital)
- Finance > Capital markets: high-yield debt offerings
- Finance > Commercial lending
- Dispute resolution > Corporate investigations and white-collar criminal defense
- Dispute resolution > Financial services litigation